Enthusiasm for AI has spilled into biotech, with numerous accounts of how the advanced technology will revolutionize the sector. But drug development is multifaceted, and some stages of the process, such as regulatory filings and clinical testing, may see limited benefit from AI in the near term. In our view, investors should keep perspective and stay focused on what matters most to the value of biotech companies: approved products backed by clinical data.
Continue reading this article?
Register for free and get access to Investment Officer International:
- Exclusive for professional investors
- Cancel anytime
- Unlimited access: web, app and newsletters
Registration takes less than 1 minute.
No payment details required
Register for free and get access to Investment Officer Luxembourg:
- Exclusive for professional investors
- Cancel anytime
- Unlimited access: web, app and newsletters
Registration takes less than 1 minute.
No payment details required
